„We seek to better understand the development and progression of neuroimmunological and neuroinfectious diseases with particular emphasis on multiple sclerosis to translate molecular findings into drug treatment and improve clinical care. In order to achieve this goal, we systematically study immunology, neurobiology and patient care using a wide methodological spectrum.“

Institute

The Institute of Neuroimmunology and Multiple Sclerosis (INIMS) at the University Medical Centre Hamburg-Eppendorf was founded 2006 based on an initiative of the Gemeinnützige Hertie-Stiftung which intended to create a translational research institute for multiple sclerosis research. Committed to the mission to better understand the aetiology and pathogenesis of multiple sclerosis and other neuroimmunological diseases and to translate this knowledge into efficacious treatments. Besides cellular and molecular research, the INIMS also sets high standards in providing patient care.

To achieve these goals, basic research is interlocked with clinical activities ensuring access to patients as well as setting up operative platforms for conducting clinical studies. The INIMS consists of three operational units: It integrates a (i) basic science institute located at the Centre for Molecular Neurobiology Hamburg (ZMNH) with a (ii) clinical research platform located at the dedicated day hospital for patients with multiple sclerosis and other neuroimmunological diseases (outpatient clinic) affiliated to the Department of Neurology; and operates (iii) a section for multiple sclerosis imaging (SeMSi) dedicated to MRI studies affiliated to the Department of Neuroradiology. The INIMS basic science institute is equipped with state-of-the art cellular and molecular biology laboratories as well as in vivo facilities focussing on immunology and neurobiology research. The INIMS closely interacts with the Department of Neurology to assure continuity in inpatient and outpatient care of neuroimmunological patients (6,500 MS patients in database), biomaterial collection (multiple sclerosis biobanking with samples of more than 2,000 patients) and continuous medical education as well as teaching of students. The imaging section is equipped with a 3T Siemens Skyra MRI scanner and a fully established infrastructure destined predominantly to multiple sclerosis diagnostics and research. Moreover, the Fraunhofer Institute IME SP operates a Biomarker and Discovery Biology platform located at the INIMS addressing biomarker development in multiple sclerosis and their treatment trials and collaborating with the INIMS in several projects, which are mainly associated with the consortium NEU2.

The main scientific goal of the INIMS is translational research – to transform biology into effective therapeutic agents for neuroimmunological diseases:

  • to study the aetiology and pathogenesis of multiple sclerosis and other neuroimmunological and neuroinfectious diseases
  • to investigate the immune system and the central nervous system and their interactions to understand mechanisms of immune cell dysregulation, neurodegeneration and neuroprotection
  • to develop new drugs and behavioural interventions for multiple sclerosis patients and to test them in multiple sclerosis treatment trials

Consortial memberships


The northern Germany based NEU² consortium was established in 2009 and has created a public-private framework, which applies biological, clinical and technological insight to identify and progress treatments for multiple sclerosis. The organization integrates existing multiple sclerosis expertise from academic centres (mainly UKE), biotechnology and pharmaceutical companies, with each member contributing one or more of their respective core clinical, scientific, or technical competencies. This provides NEU² as a whole with the necessary know-how to discover new therapies and diagnostic approaches for multiple sclerosis and progress them to the clinic in order to benefit patients. NEU² has meanwhile assembled several collaborative discovery and development projects. The projects are partially funded by the Federal Ministry of Education and Research (BMBF) and NEU² has extended its initial project portfolio ranging from immunomodulatory approaches to tolerisation and neuroprotective treatment modalities in multiple sclerosis and beyond. NEU² aims at innovative approaches based on novel mechanisms of action, new ways of delivery and improved safety.






Open positions


If you are interested in joining the INIMS, please send an email to Manuel Friese, and include your CV and a brief statement of why you are interested in our work. We look forward to hearing from you!

Send email

Clinician-Scientist in Multiple Sclerosis research

The offered position is part of the Clinician-Scientist program offering young clinicians the possibility to work in a mentored 3-year research project while proceeding with their residency in Neurology.

Read more

PhD Student Position in Neuroimmunology

The offered position is part of an UKE-based collaborative research consortium on “identification of immune mechanisms in diseases with sex specific differences” and aims at investigating such differences in T cells in the pathogenesis of MS and its mouse model (EAE).

Read more

Funding









Disclosure of Industry Relationships

We believe that public accountability is important for patients in order to decide which factors might have potentially influenced their medical care. Besides the science of medicine, patients need to be empowered to understand decisions and participate as equal partners in every discussion that affects their healthcare. Therefore, we feel that disclosing industry relationships is our duty to be accountable and socially responsible to those we treat in medicine.

Personal honoraria received in 2014:
Friese EUR 0
Gold EUR 0
Heesen EUR 2,000 (Merck Serono, Novartis)
Contributions from industry partners in clinical trials in 2014:
Alpinia Laudanum Institute of
Phytopharmaceutical Sciences AG
EUR 86,000
Biogen Idec EUR 102,646
Genzyme GmbH EUR 12,000
Merck Serono GmbH EUR 15,000
Novartis Pharma GmbH EUR 66,500
TEVA GmbH EUR 4,968
Contributions from industry partners as part of sponsorship in 2014:
Biogen Idec EUR 500
Contributions from industry partners as part of donations in 2014:
Bayer Vital EUR 1,000
Novartis Pharma GmbH EUR 500
Contributions from non-profit organizations in 2014:
Cedars Sinai Medical Center, Los Angeles EUR 18,443
Personal honoraria received in 2015:
Friese EUR 865 (Novartis)
Gold EUR 0
Heesen EUR 4,477 (Merck Serono)
Contributions from industry partners in clinical trials in 2015:
Alpinia Laudanum Institute of
Phytopharmaceutical Sciences AG
EUR 18,235
Biogen Idec EUR 111,894
Genzyme GmbH EUR 51,240
Merck Serono GmbH EUR 14,573
Novartis Pharma GmbH EUR 27,598
TEVA GmbH EUR 14,041
Contributions from industry partners as part of sponsorship in 2015:
none
Contributions from industry partners as part of donations in 2015:
Novartis Pharma GmbH EUR 1,000
Biogen Idec EUR 476
Personal honoraria received in 2016:
Friese EUR 0
Gold EUR 0
Heesen EUR 2,563 (Novartis, Teva)
Stellmann EUR 2,850 (Biogen, Genzyme)
Contributions from industry partners in clinical trials in 2016:
Alpinia Laudanum Institute of
Phytopharmaceutical Sciences AG
EUR 22,000
Novartis Pharma GmbH EUR 20,000
Genzyme GmbH EUR 30,000
Roche EUR 237,000
Contributions from industry partners as part of sponsorship in 2016:
Biogen Idec EUR 1,500
Genzyme GmbH EUR 1,500
Novartis Pharma GmbH EUR 1,000
Roche EUR 500
Contributions from industry partners as part of donations/prizes in 2016:
Biogen Idec EUR 50,000
Novartis Pharma GmbH EUR 50,000
Contributions from non-profit organizations in 2016:
Deutsche Rentenversicherung EUR 147,687
DMSG EUR 45,000
RIMS EUR 60,000

Location

Copyright 2015. Institute of Neuroimmunology and Multiple Sclerosis. Impressum